Skip to main navigation
Skip to search
Skip to main content
University of Galway Home
Help & FAQ
Link opens in a new tab
Search content at University of Galway
Home
Profiles
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Courses
New Directions in the Treatment of Imatinib Failure and/or Resistance
Francis J. Giles
University of Texas Health Science Center San Antonio
Research output
:
Contribution to a Journal (Peer & Non Peer)
›
Article
›
peer-review
14
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New Directions in the Treatment of Imatinib Failure and/or Resistance'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Imatinib
100%
Chronic Myelogenous Leukemia
50%
Dasatinib
50%
Nilotinib
50%
Treatment Option
50%
Clinical Study
25%
Interferon Alfa
25%
Diseases
25%
Histone Deacetylase Inhibitor
25%
Allogeneic Hematopoietic Stem Cell Transplantation
25%
Cytotoxic Chemotherapy
25%
Phase II Trials
25%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Imatinib
100%
Nilotinib
50%
Chronic Myeloid Leukemia
50%
Dasatinib
50%
Clinical Study
25%
Alpha Interferon
25%
Phase II Trials
25%
Diseases
25%
Histone Deacetylase Inhibitor
25%
Tolerability
25%
Cytotoxic Chemotherapy
25%
Neuroscience
Imatinib
100%
Tyrosine Kinase Inhibitor
100%
Myeloid
50%
Nilotinib
50%
Dasatinib
50%
Hematopoietic Cell
25%
Interferon Alfa
25%
Histone Deacetylase Inhibitor
25%
Chemotherapy
25%